Safeguarding Public Health: FDA Cracks Down on Unauthorised Product Advertisements
The Food and Drugs Authority (FDA) in the Ashanti Region has issued a stern warning to media organisations and product manufacturers, emphasising that public health will not be compromised for commercial gain. Nathaniel Nana Kwabena Nkrumah, the Ashanti Regional Head of the FDA, highlighted the critical need for adherence to regulatory frameworks governing product advertisements, particularly for alcoholic beverages and medicinal items.
During a recent training session organised for morning show hosts in the Kumasi Metropolis, Mr. Nkrumah underscored that manufacturers must secure FDA approval for their products not only through registration but also before any advertisement is aired. This directive is in line with the provisions of the Public Health Act, 2012 (Act 851).
Media’s Crucial Role and Legal Liability
Mr. Nkrumah stressed that media hosts, especially those presenting morning shows on radio, bear significant legal responsibility. They can be held liable under the law if they permit advertisements that do not meet regulatory compliance to be broadcast on their platforms. The FDA has intensified its monitoring efforts across radio stations in the region and has identified persistent violations, often stemming from a lack of awareness among some media practitioners regarding these regulations.
“We monitor radio stations from morning to evening, and that is how we identify these challenges,” stated Mr. Nkrumah. “Some of the issues discussed are not known to the media, and this training is to equip them to identify non-compliant advert scripts and reject them.”
Escalating Sanctions for Non-Compliance
The consequences for regulatory breaches are substantial. Administrative fines for violations begin at GH¢25,000 and can escalate depending on the severity of the offence. However, Mr. Nkrumah expressed concern that some manufacturers appear to view these fines as a mere operational cost, continuing to advertise products with unsubstantiated claims.
The FDA’s authority extends beyond financial penalties. “The law goes beyond fines. The FDA has the power to cancel the registration of such products, and once that is done, they cannot be advertised or sold,” he asserted. For persistent offenders, the Authority is prepared to escalate sanctions to include prosecution, as the Public Health Act prescribes severe penalties, including the possibility of long-term imprisonment.
Ashanti Region: A “No-Go Area” for Regulatory Flouters
Mr. Nkrumah declared the Ashanti Region a “no-go area” for individuals and companies attempting to circumvent regulatory requirements. He affirmed that enforcement measures would be significantly strengthened to deter non-compliance.
The engagement with media professionals was deemed crucial, given the media’s extensive reach and influence as a key partner in public education. “Once you educate journalists, you educate the public. That alone can solve a significant part of the problem,” he emphasised.
Preventing Exploitation and Upholding Health Standards
The FDA head cited instances where misleading product claims have resulted in serious health consequences for consumers. He reiterated the Authority’s commitment to preventing the exploitation of the public for financial gain. “Human health cannot be exchanged for money. We will not tolerate any action that puts lives at risk,” he declared.
Media practitioners are urged to strictly adhere to FDA guidelines. This includes diligently verifying the approval status of products before authorising advertisements to be aired. By doing so, they play a vital role in safeguarding public health and ensuring that consumers are not misled by inaccurate or unsubstantiated claims. The FDA’s proactive approach aims to create a more responsible advertising landscape where consumer well-being is paramount.
